Flotetuzumab

BIOLOGICAL6 trials

Conditions

AMLAML, Adult RecurrentAcute Myeloid LeukemiaLeukemia, Myeloid, AcuteRecurrent Acute LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 1

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Active, not recruitingNCT04158739

Children's Oncology GroupRecurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Start: 2020-01-22End: 2026-03-31Updated: 2026-01-23

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

CompletedNCT04681105

City of Hope Medical CenterRecurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm +14

Start: 2020-11-18End: 2025-08-05Updated: 2026-01-28

Post-transplant Flotetuzumab for AML

CompletedNCT05506956

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLeukemia, Myeloid, Acute

Start: 2022-10-20End: 2024-06-18Updated: 2025-09-12

Phase 2

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

TerminatedNCT04582864

Washington University School of MedicineRelapsed Acute Myeloid Leukemia

Start: 2021-05-20End: 2024-07-26Updated: 2024-12-06

Study to Assess an Interphase Cycle With Flotetuzumab.

WithdrawnNCT05063123

Stichting Hemato-Oncologie voor Volwassenen NederlandAML

Start: 2022-01-31End: 2026-12-31Updated: 2021-12-22

Unknown Phase

Flotetuzumab Expanded Access Program

NCT04678466

MacroGenicsAcute Myeloid Leukemia, AML, AML, Adult Recurrent

Updated: 2022-05-31

Related Papers

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.